Update on glasdegib in acute myeloid leukemia – broadening horizons of Hedgehog pathway inhibitors

Numerous new emerging therapies, including oral targeted chemotherapies, have recently entered the therapeutic arsenal against acute myeloid leukemia (AML). The significant shift toward the use of these novel therapeutics, administered either alone or in combination with intensive or low-intensity chemotherapy, changes the prospects for the control of this disease, especially for elderly patients. Glasdegib, an oral Hedgehog pathway inhibitor, showed satisfactory response rates associated with moderate toxicity and less early mortality than standard induction regimens in this population. It was approved in November 2018 by the FDA and in June 2020 by the EMA for use in combination with low-dose cytarabine as a treatment of newly-diagnosed AML in patients aged ≥ 75 and/or unfit for intensive induction chemotherapy. The current paper proposes an extensive, up-to-date review of the preclinical and clinical development of glasdegib. Elements of its routine clinical use and the landscape of ongoing clinical trials are also stated.

Keywords: glasdegib, PF-04449913, PF-913, acute myeloid leukemia, Hedgehog pathway, smoothened

INTRODUCTION

The hedgehog (HH) intracellular signaling pathway, first described in Drosophila in 1980 (1), has a significant role in normal embryonic development and adult stem cell persistence (2–4). The physiological HH pathway (Fig. 1) is dependent upon 3 known human ligands, triggering a concentration- and gradient-dependent response (3). They are lipid-modified secreted proteins named Sonic HH (SHH), Indian HH (IHH) and Desert HH (DHH) (4). These ligands can bind to negative-regulator receptors named Patched (PTCH1 and PTCH2, 12-pass transmembrane proteins) (5), resulting in the derepression of the G-protein-like transducer Smoothened (SMO, a 7-pass transmembrane protein) (6). Intracellular glioma zinc finger transcription factors (GLI1, GLI2 and GLI3) are then activated by SMO and promote the expression of several HH-pathway-related genes, such as BCL2, cMYC and SNAIL (7–9). Overall, expression levels of GLI1 are well correlated with the HH pathway.

*Correspondence; e-mail: cyril.fersing@icm.unicancer.fr
HH pathway and GLI abnormal signaling are associated with dysregulation of cell regeneration and redifferentiation. Thus, these modifications can be found in several types of cancer (11). Among these diseases, the role of deviant HH signaling in hematological cancers has been particularly emphasized, especially in myeloid malignancies (12–14). In acute myeloid leukemia (AML), HH pathway overexpression was objectified in myeloblastic cells (15, 16) and was associated with cell survival, chemoresistance and radiotherapy resistance (17–21). Therefore, the HH pathway and, more specifically, the SMO protein appeared as a promising pharmacological target, which may be inhibited by small molecules. Numerous derivatives have been developed as SMO inhibitors (22), the most widely used in oncology being vismodegib, sonidegib and glasdegib. Although preclinical studies have shown significant efficacy of vismodegib and sonidegib in hematological cancer models (21, 23, 24), these two drugs had little clinical evaluation in patients with leukemic pathologies (25). On the other hand, glasdegib has been studied more intensively as a potential treatment in acute myeloid leukemia. Following the positive results of phase II clinical trials (26), glasdegib received its first approval in the USA on 21 November 2018 for its use in the combination with low dose cytarabine (LDAC) in newly-diagnosed AML patients ≥ 75 years or with comorbidities that contraindicate the use of intensive induction chemotherapy (IC) (27, 28). This approval was almost simultaneous with the authorization of ivosidenib and gilteritinib in the treatment of AML and came one year after the approval of midostaurin, enasidenib and gemtuzumab ozogamycin as therapeutic alternatives in
AML. In this context, the way in which these molecules should be used and their respective advantages have given rise to much debate (29–31). The purpose of this review is to provide a comprehensive update on glasdegib as an active ingredient, from its discovery to the practical considerations of its therapeutic use in AML, with particular emphasis on its clinical evaluation.

**PHARMACOLOGY AND PRECLINICAL STUDIES**

Glasdegib, formerly PF-04449913 or PF-913, was initially identified by Munchhof et al. among a small series of benzimidazole-based Smoothened inhibitors (32). It resulted from the optimization of a former hit molecule with suboptimal physicochemical properties (33). In addition to preserved *in vitro* efficacy (IC$_{50}$ in Gli-luciferase reporter assay is 5 nmol L$^{-1}$), glasdegib also displayed good *in vitro* microsomal stability, 9% free fraction in plasma and promising physicochemical properties (Table I). According to *in vivo* pharmacokinetic studies in rats and dogs, glasdegib was predicted to have good PK properties in humans (1.03 mL min$^{-1}$ kg$^{-1}$ plasma clearance, 2.7 L kg$^{-1}$ volume of distribution, 30 h half-life and 55% oral bioavailability) along with excellent potency.

In a preclinical study involving a PTCH1+/−p53 mouse model of medulloblastoma and human patient-derived xenograft models, glasdegib displayed potent dose-dependent inhibition of the HH pathway, resulting in stable tumor regression (34). Glasdegib-treated medulloblastoma allografts had reduced levels of Gli1 gene expression and downregulation of genes linked to the Hh signaling pathway. This GLI1 downregulation is consistent

<table>
<thead>
<tr>
<th>Molar mass (g mol$^{-1}$)</th>
<th>374</th>
</tr>
</thead>
<tbody>
<tr>
<td>Measured log D</td>
<td>2.48</td>
</tr>
<tr>
<td>Gli-luciferase reporter in C3H10T1/2 IC$_{50}$ (nmol L$^{-1}$)</td>
<td>5</td>
</tr>
<tr>
<td>Human microsomes CLi (mL min$^{-1}$ kg$^{-1}$)</td>
<td>6.3</td>
</tr>
<tr>
<td>Human plasma protein binding (% free)</td>
<td>9.1</td>
</tr>
<tr>
<td>Ames test</td>
<td>Negative</td>
</tr>
<tr>
<td>Micronucleus assay</td>
<td>Negative</td>
</tr>
</tbody>
</table>

**Table I. Early in vitro data and preclinical in vivo pharmacokinetics of glasdegib**

<table>
<thead>
<tr>
<th>In vivo pharmacokinetics</th>
<th>In rat</th>
<th>In dog</th>
</tr>
</thead>
<tbody>
<tr>
<td>CL (mL min$^{-1}$ kg$^{-1}$)</td>
<td>31</td>
<td>3.9</td>
</tr>
<tr>
<td>$V_{ss}$</td>
<td>4.8</td>
<td>4.3</td>
</tr>
<tr>
<td>$T_{1/2}$ (h)</td>
<td>1.4</td>
<td>2.9</td>
</tr>
<tr>
<td>F (%)</td>
<td>33</td>
<td>68</td>
</tr>
</tbody>
</table>

IC$_{50}$ – half-maximal inhibitory concentration, CLi – intrinsic clearance, CL – plasma clearance, $V_{ss}$ – steady state volume of distribution; $T_{1/2}$ – plasma terminal half-life; F – oral bioavailability.
with the results subsequently obtained in clinical trials (35, 36), however, glasdegib’s mode of action remained unclear at the cellular and molecular level. Thus, the pharmacology of this drug was studied on a Drosophila model that confirmed its SMO inhibition activity (37). As a consequence, blood cell homeostasis was disrupted in a way that could cause, in humans, leukemic stem cells (LSC) to exit from the bone marrow. These LSC, known to persist beyond conventional treatment cessation and to result in a relapse in myeloid diseases such as AML (38, 39), could enter the bloodstream and become sensitive to therapeutic agents (12, 40). Similar results were obtained in vitro, also presenting bone marrow stromal cells as a possible target of Smo inhibitors to decrease the quiescent LSC population (41). In an AML xenograft mouse model, glasdegib showed synergistic action with LDAC in inhibiting tumor growth and limiting the percentage of CD45+/CD33+ blasts in the bone marrow (41). As previously proposed, glasdegib-treated AML cells showed increased sensitivity to chemotherapeutic agents such as cytarabine, highlighting the benefit of glasdegib plus chemotherapy association. Effects of glasdegib on LSC quiescence, survival and self-renewal were also investigated on mice intrahepatically transplanted with blast crisis chronic myeloid leukemia (CML) LSCs (42). Mice were treated for 14 days by daily oral gavage with dasatinib alone (50 mg kg⁻¹) or glasdegib (100 mg kg⁻¹) with or without dasatinib (50 mg kg⁻¹). Combination treatment with glasdegib and dasatinib revealed a significant decrease in LSC hepatic engraftment compared with glasdegib or dasatinib alone. Cell cycle analysis also demonstrated a reduction in quiescent human leukemic cells in the peripheral blood and in the bone marrow following SMO inhibitor treatment (43). Like in the previous study, Chaudhry et al. documented the benefits of using glasdegib in an association, emphasizing the key role of Gli3r for the therapeutic effect of SMO antagonists in AML (44). They demonstrated that GLI3 gene expression was epigenetically silenced in most AML, causing glasdegib ineffectiveness. However, treatment with hypomethylating agents (HMA), such as decitabine, restored GLI3 expression and therefore glasdegib efficacy. Similar results were also obtained concerning GLI2 expression (45, 46). Some clinical trials’ protocols presented subsequently are based on this mechanistic rationale for combining chemotherapeutic agents and SMO antagonists in AML.

**CLINICAL EVALUATION**

**Phase I**

After a first-in-patient preliminary evaluation (47), Martinelli et al. reported an open-label, multi-center phase Ia dose-escalation study (NCT00953758) to assess first-cycle dose-limiting toxicities (DLTs) and the recommended phase II dose (RP2D) of glasdegib (35, 47). Forty-seven patients have been enrolled at doses from 5 mg to 600 mg orally once daily, for 1 to 537 days. Patients had refractory, resistant, or intolerant selected hematologic malignancies such as AML (n = 28), CML (n = 5), myelodysplastic syndrome (MDS, n = 6), myelofibrosis (MF, n = 7) or chronic myelomonocytic leukemia (CMML, n = 1). One of the AML patients achieved complete remission with incomplete blood count recovery (CRi, bone marrow blast count decreased from 92 to 1 %), seven AML patients had a stable bone marrow blast count, one patient with low-risk MDS achieved a significant reduction in spleen size and a hematologic improvement in platelets (from 98.5 to 369 × 10⁹ L⁻¹) and neutrophils, five patients with MF attained stable disease, and one patient with T3151 lymphoid

blast crisis CML achieved a major cytogenetic response with loss of the T3151 mutation. The gene expression profile analysis of bone marrow LSC progenitors evidenced that glasdegib triggered HH pathway genes (Gas1, Kif 27) up-regulation (48) and chemoresistance genes (ABCA2, Bcl2) downregulation (49). Overall, glasdegib showed preliminary clinical activity in nearly half of the patients in the study. Four patients discontinued the study due to a treatment-related adverse event (TRAE): hemorrhagic gastritis (10 mg group), decreased appetite (40 mg group), peripheral oedema (400 mg) and decreased weight (600 mg group). The majority of AEs were of G1/2 severity, including dysguesia (28 %), decreased appetite (19 %), alopecia (15 %), diarrhea (13 %), nausea (13%) and vomiting (11 %). Glasdegib PK data indicated a dose-proportional profile, with a $T_{\text{max}}$ of 1–2 hours, a mean half-life of about 24 hours and a large volume of distribution (250–480 L). Steady-state was achieved in 8 days and the median accumulation ratio ranged from 1.3 to 2.9. Based on the safety, tolerability, pharmacodynamic analysis and preliminary clinical activity reported, the RP2D for treatment with glasdegib was established to be 200 mg or lower once daily.

In view on the encouraging results of this first study, Minami et al. reported the partial results of an open-label, multicenter phase I trial (NCT02038777) of glasdegib in 13 Japanese patients with AML ($n = 7$), MDS ($n = 4$), CMML ($n = 1$) or MF ($n = 1$) (50). Glasdegib was administered orally once a day at 25 mg, 50 mg or 100 mg for 36 to 332 days and didn’t cause any DLT, although treatment was permanently discontinued in 4 patients due to AE (3 at 50 mg and 1 at 100 mg). Observed AEs were very consistent with those reported by Martinelli et al. (35). Preliminary clinical activity data showed that 1 AML patient achieved morphological complete remission (CR) in the 100 mg group and 4 AML patients (1 each in the 20 mg and 50 group, 2 in the 100 mg group) achieved stable disease. One MDS patient in the 100 mg group achieved marrow complete remission and 2 MDS patients (1 each in the 25 mg and 100 mg group) achieved stable disease. Glasdegib PK parameters were comparable to those previously reported (dose-proportional kinetics, $T_{\text{max}} = 2–4$ h, $T_{1/2} = 20.7 ± 7.7$ h).

The first combination of glasdegib with standard chemotherapy in patients was reported by Savona et al. (51). In an open-label, multicenter, dose-escalation, phase Ib study (BRIGHT AML 1003, NCT01546038), glasdegib 100 mg or 200 mg was administered orally, once a day during 2–567 days, in combination with LDAC ($n = 23$, arm A), decitabine ($n = 7$, arm B) or cytarabine/daunorubicin ($n = 22$, arm C). Most patients had a diagnosis of AML (87 %, 71 % and 91 % of patients in arm A, B and C, respectively); others were MDS patients. In this population, a clinically beneficial response was observed in 2 (10 %), 3 (60 %) and 12 (60 %) patients in arms A, B and C, respectively. However, these response rates were not significantly different than those expected with standard treatment alone. Overall survival (OS) was 4.4, 11.5 and 34.7 months in arm A, B and C, respectively. Analysis of gene mutation profiles in responders and non-responders did not indicate that clinical response could be predicted by any particular mutation profile. In the same way, minimal or inconsistent changes were evident in circulating cytokines in these patients. No DLTs were observed in arm A and arm B, but 1 DLT (grade 4 neuropathy) occurred in arm C. The most common non-hematologic TRAEs were mostly graded 1 and 2 in all arms. Muscle spasms, considered the most frequent TRAE, were observed in 49 to 76 % of patients. Based on the tolerability, efficacy and PK profile of glasdegib in combination with chemotherapy regimens, the authors selected an RP2D of 100 mg daily as a basis for further evaluations in these patient populations.
To compensate for the low number of patients with MDS in this study, another open-label phase Ib clinical trial aimed to enroll more MDS patients. In this BRIGHT MDS & AML 1012 study (NCT02367456), early trends suggested an acceptable safety profile for the combination of glasdegib 100 mg daily with azacytidine (AZA) 75 mg m\(^{-2}\) day 1–7 every 25 days (52, 53). The number of CR (3 for 12 patients in 2015, 5 for 30 patients in 2019) appeared favorable in comparison with AZA alone. Analysis of early hematopoietic recovery and transfusion independence showed that early platelet recovery was correlated with response to treatment (54). Among patients with MDS and AML (both \(n = 30\) in 2019), respectively, 54 % (7/13) and 64 % (9/14) of evaluable transfusion-dependent patients at baseline became transfusion-independent after an average treatment duration of 5 months. In addition to this early marrow recovery, the glasdegib + ASA combination did not seem to impact negatively the health-related quality of life of patients (55). Definitive conclusions of this study are still pending.

Gerds et al. reported a single-arm, lead-in cohort, open-label phase Ib/II trial (NCT02226172) of glasdegib in patients with primary or secondary MF previously treated with at least 1 JAK inhibitor (56). Twenty-one patients received 100 mg glasdegib orally for up to 24 weeks. Approximately 40 % of patients achieved > 20 to 30 % reduction in symptoms, suggesting that glasdegib could have a significant benefit in improving MF-related clinical manifestations. However, mean spleen volume measured by MRI or CT at weak 24 suggested this treatment may not sustainably decrease spleen volume in this patient population (mean percentage change from baseline in spleen volume was +10.92 %; 3 patients with stabilization or reduction in spleen size). All 21 patients experienced one or more TRAE, causing permanent treatment discontinuation for 12 (57.1 %) patients, mostly due to muscle spasms (\(n = 6\)) and dysgeusia (\(n = 3\)). Although the frequencies of TRAEs in this population were higher than those reported in previous studies, the toxicity profile of glasdegib was considered manageable. The authors proposed to consider alternative dosing schedules as a strategy to increase tolerability of glasdegib in similar populations.

Glasdegib was also evaluated in 23 patients with various advanced solid tumors, through an open-label, multicenter, phase I study (NCT01286467, 36). Eight patients achieved stable disease and glasdegib was well tolerated at doses of 80–320 mg, once daily. TRAEs and PK parameters were consistent with previous statements.

**Phase II**

After the phase I studies of glasdegib in myeloid malignancies, this SMO inhibitor was evaluated in combination within larger patient cohorts. In an open-label, phase II, multicenter trial (BRIGHT AML 1003 “intensive arm”, NCT01546038), previously untreated patients with AML (\(n = 66\)) or high-risk MDS (\(n = 5\)) received glasdegib 100 mg orally once daily in 28-days cycles (range 10–501 days), with intravenous daunorubicin 60 mg m\(^{-2}\) on days 1–3 and continuous intravenous cytarabine (100 mg/1.73 m\(^{2}\)) on days 1–7 of every cycle (57). Of the 69 patients included in the full analysis set, 46.6 % (80 % CI 38.7–54.1) achieved CR, among which 40.0 % (31.9–48.1) of patients aged ≥ 55 years and 88.9 % (75.5–100.0) of patients aged < 55 years. These values are within the range of those reported for other AML therapies, or even slightly better (58–60). The median duration of CR was 94 (range 1–480) days in all patients and 103 (1–480) and 50 (1–268) days in patients aged ≥ 55 years and < 55 years, respectively. These results have certainly contributed to the positioning...
of glasdegib as a therapeutic alternative in AML for elderly populations (61). Overall, 35 (54.7 %) AML patients and 2 (40 %) MDS patients achieved CR/CRi. The combination of glasdegib with cytarabine and daunorubicin caused mostly low-grade diarrhea and nausea, however, more than 80 % of patients experienced grade 3 adverse events (AEs). Across all patients, 14 (20.3 %) and 25 (36.2 %) patients permanently or temporarily, respectively, discontinued study treatments (glasdegib and/or cytarabine/daunorubicin) due to AEs. Five (7.2 %) patients had dose reductions due to AEs. Expression levels of several genes were investigated and showed that FLT3 mutations and high PTCH1 expression levels were correlated with a better response (62). Conversely, mutations in TP53, NF1 or CREBBP were associated with a negative response (63).

The same authors also reported the results from another portion of the aforementioned phase II clinical trial, comparing low dose cytarabine (LDAC) with or without glasdegib in AML and MDS patients under randomized conditions (26). In this section of the BRIGHT AML 1003 trial (NCT01546038), LDAC was administered subcutaneously for 10 days per 28-day cycles, as monotherapy for 41 patients and associated with 100 mg glasdegib administered orally every day of the cycle for 84 patients (Fig. 2). In each group, over half of the patients were aged > 75 years. After the follow-up period (21.7 months and 20.1 months on average for glasdegib/LDAC arm and LDAC arm, respectively), the median (80 % CI) OS was 8.8 (6.9–9.9) months with combination therapy and 4.9 (3.5–6.0) months with LDAC alone. This significant OS improvement is reflected in a 49 % reduction in the risk of death for patients treated with glasdegib/LDAC, compared to LDAC alone. These data have been refined by treatment-response and exposure-response analyses, also specifying that variability in glasdegib exposures did not impact the risk of death (64). CR was achieved in 17 % (n = 15) and 2.3 % (n = 1) patients in glasdegib/LDAC arm and LDAC arm, respectively. Noteworthy, the CR rate in the LDAC arm was quite lower than previously reported in other trials (65–67), with no evident reason. The median time to CR among patients receiving the combination therapy was 1.9 months, with a 9.9-month median duration of CR. In the MDS group, patients treated with combination therapy (n = 10) achieved a 22.8 % reduction in the risk of death relative to LDAC alone (n = 6), which was considered as an encouraging result despite the small sample size. The addition of glasdegib to LDAC was generally well tolerated, with a manageable safety profile even in elderly patients. Nevertheless, 9 out of 10 and 3 out of 6 patients permanently discontinued study treatments due to TRAEs in combination therapy arm and LDAC arm, respectively.

Fig. 2. Design and main results of the randomized, placebo-controlled section of the phase 2 BRIGHT AML 1003 study.
This first randomized phase II study highlighted the combination of glasdegib with LDAC as a compelling therapeutic approach, especially for AML patients ineligible for IC (68). Long-term outcomes in the same patients (43.4 months and 42.0 months follow-up period on average for glasdegib/LDAC arm and LDAC arm, respectively) confirmed the previous results (median OS = 8.3 vs. 4.3 months) (69). A post-hoc analysis also showed that the addition of glasdegib to LDAC vs. LDAC alone was associated with improved OS both in patients with de novo AML and secondary AML (70). Overall, although other combination therapies like HMA with venetoclax have been associated with much higher response rates in AML (71), the clinical efficacy and good safety profile of the glasdegib/LDAC combination assessed in this study were pivotal evidence for glasdegib regulatory approval (72). Late follow-up analyses remained consistent with the primary findings (73). In 2020, Cortes et al. published a post-hoc analysis suggesting possible clinical benefits of glasdegib in the absence of CR (74), as the addition of glasdegib to the LDAC trend to improve OS versus LDAC alone (median OS = 5.0 and 4.1, respectively) in patients who did not achieve CR. Moreover, durable recovery of the absolute neutrophil count, hemoglobin and platelets was observed in more patients receiving combination therapy, though improved OS could not be obviously correlated to the reach of a specific blood count threshold (75).

Tremblay et al. reused the data of the previous study and have resorted to indirect or simulated treatment comparison methods to compare the effectiveness of glasdegib + LDAC association with HMAs in AML (76). Published clinical trials evaluating AZA or decitabine vs. LDAC in elderly AML patients ineligible for IC were used to obtain comparative data. Despite the risk of imperfect adjustment depending on the model applied, this indirect comparison compensates for the absence of direct, head-to-head trial results. Based on this methodology, glasdegib associated with LDAC tended to demonstrate consistently favored OS hazard ratios (HR) over either AZA or decitabine (HR = 0.424; 95% CI = 0.228–0.789 and HR = 0.505; 95% CI = 0.269–0.949, respectively). A second study performed an indirect treatment comparison between glasdegib + LDAC and AZA depending on bone marrow blasts count (77). Both unadjusted HRs and HRs corrected for the potential imbalances at baseline between the trials suggested that glasdegib + LDAC association may be preferred over AZA, regardless of bone marrow blasts count, in previously untreated, chemotherapy-ineligible AML patients.

Glasdegib was also evaluated in a single-center, open-label phase II study (NCT01842646) as a monotherapy (100 mg daily oral dose during 28 days, up to 4 cycles) in 35 patients (median age = 73 years) with MDS, CMML or AML (74, 15 and 11%, respectively) who have experienced refractory disease, progression or relapse following prior HMA therapy (78, 79). Although the treatment was safe and well-tolerated, only 6% of patients (n = 2) achieved an objective response. Nineteen patients had stable disease (median OS = 20.6 months), however, the limited activity of glasdegib as a single agent supports its greater interest in combination therapy, as previously stated (80).

Finally, Kent et al. conducted a dual-center phase II study evaluating the ability of glasdegib to prevent post-allogeneic stem cell transplantation (ASCT) relapse in 31 AML and MDS patients at high risk for this outcome (81). Patients received 100 mg oral glasdegib daily for 28-day cycles, starting from day 28 to 100 post-ASCT and continuing for 1 year in the absence of relapse or intolerance. The median time on treatment before permanent discontinuation was 142 days (range, 28–336 days). More than 90% of patients (n = 28) experienced at least 1 AE attributable to glasdegib and half of the patients (n = 16) experienced
at least 1 grade ≥ 2 AE. Two-thirds of patients \( n = 19 \) had glasdegib interruptions because of AEs and 5 had dose reductions, mostly because of cramping or myalgia. The significant quality-of-life issues objectified in this study and caused by glasdegib, possibly due in part to interactions with the multiple concomitant medications routinely administered post-ASCT, suggested a probable risk of poor compliance with treatment. Overall, among these 31 patients, 1- and 2-year OS rates were 64.5 and 46.8 \%, respectively. Relapse-free survival rates were 41.9 and 31.5 \%, respectively. Eight patients had a measurable residual disease relapse at a median time of 180.5 days post-ASCT and 17 patients experienced a morphological relapse at a median time of 333 days post-ASTC. This pilot study, although not randomized, suggested limited ability for glasdegib to prevent relapse in a high-risk post-ASCT setting and highlighted a non-optimal tolerance profile that could affect both adherence and quality of life.

**Phase III**

The BRIGHT AML 1019 trials (NCT03416179) were designed as two independent, phase III, randomized (1:1), double-blind studies evaluating the efficacy of oral glasdegib 100 mg once daily or placebo plus one or two standard chemotherapy regimens in adults with untreated AML (Fig. 3) (82, 83). In the intensive study \( n = 200:200 \), patients received glasdegib or placebo for up to two years or until disease progression, treatment failure, hematological relapse, toxicity, elimination of measurable/minimal residual disease, patient refusal or death. Glasdegib was combined with cytarabine and daunorubicin (‘7 + 3’ induction therapy followed by 1 to 4 28-day cycles of consolidation therapy with cytarabine alone). In the nonintensive study \( n = 160:160 \), patients received glasdegib or placebo plus AZA given subcutaneously or intravenously for 7 days in 28-day cycles, for at least 6 cycles or until disease progression, toxicity, patient refusal or death. Assignment to the intensive or nonintensive study was decided by the investigator.

In each study, eligible patients could receive allogeneic stem cell transplantation and may continue glasdegib or placebo up to 2 years after randomization. The results of this

![Fig. 3. Design of the randomized, placebo-controlled phase 3 BRIGHT AML 1019 study.](image-url)
Table II. Completed clinical trials with glasdegib

<table>
<thead>
<tr>
<th>Study (NCT number)</th>
<th>Phase</th>
<th>Patients (n)</th>
<th>Study cohort</th>
<th>Regimen</th>
<th>ORR (%)</th>
<th>CR (%)</th>
<th>PFS (months)</th>
<th>OS (months)</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT01286467</td>
<td>1</td>
<td>23</td>
<td>Solid tumors</td>
<td>GD 80, 160, 320 or 640 mg/day</td>
<td>0</td>
<td>0</td>
<td>NA</td>
<td>NA</td>
<td>36</td>
</tr>
<tr>
<td>NCT00953758</td>
<td>1a</td>
<td>47</td>
<td>AML, CML, MDS, MF, CMML</td>
<td>GD 5 to 600 mg/day</td>
<td>2.12</td>
<td>NA</td>
<td>4.4 (MF)</td>
<td>NA</td>
<td>35, 47, 48, 49</td>
</tr>
<tr>
<td>NCT02038777</td>
<td>1</td>
<td>13</td>
<td>AML, MDS, CMML, MF</td>
<td>GD 25 or 50 or 100 mg/day</td>
<td>15.38</td>
<td>7.7</td>
<td>NA</td>
<td>NA</td>
<td>50</td>
</tr>
<tr>
<td>NCT02367456</td>
<td>1b</td>
<td>60</td>
<td>AML, MDS</td>
<td>GD 100 mg/day + AZA 75 mg/m²/day</td>
<td>31.7</td>
<td>16.7 in MDS (n = 30)</td>
<td>NA</td>
<td>6-months probability: 70.0 % (AML) 78.9 % (MDS)</td>
<td>52, 53, 54, 55</td>
</tr>
<tr>
<td>NCT02226172</td>
<td>1b/2</td>
<td>21</td>
<td>MF</td>
<td>GD 100 mg/day</td>
<td>9.5</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>56</td>
</tr>
<tr>
<td>NCT01546038</td>
<td>2</td>
<td>69</td>
<td>AML, MDS</td>
<td>GD 100 or 200 mg/day + AraC/DNR (Arm A)</td>
<td>62.3</td>
<td>46.6</td>
<td>NA</td>
<td>NA</td>
<td>57, 62, 63</td>
</tr>
<tr>
<td>NCT01842646</td>
<td>2</td>
<td>35</td>
<td>MDS, CMML, AML</td>
<td>GD 100 mg/day</td>
<td>6</td>
<td>0</td>
<td>6.4</td>
<td>10.4</td>
<td>78, 79</td>
</tr>
<tr>
<td>NCT01841333</td>
<td>2</td>
<td>31</td>
<td>AML, MDS</td>
<td>GD 100 mg/day post-ASCT</td>
<td>NA</td>
<td>NA</td>
<td>2-years probability: 31.5 %</td>
<td>2-years probability: 46.8 %</td>
<td>81</td>
</tr>
</tbody>
</table>

study, when available, may support the expansion of the current registration of glasdegib to include treatment of AML patients in combination with cytarabine plus daunorubicine or AZA, in addition to its already approved indication. A summary of the main results obtained from clinical trials with glasdegib is given in Table II.

Pharmacokinetics and drugs interactions

Using samples collected from initial phase I and II studies (35, 36, 51), Lin et al. developed a PK model to characterize glasdegib kinetic behavior in patients and to predict the sources of variability in its PK parameters (84, 85). Data from 269 patients with various haematological or solid tumor malignancies (median age and weight was 69 years and 78.6 kg; median creatinine renal clearance was 80.9 mL min⁻¹; normal hepatic function in 81 % patients) showed that glasdegib followed a two-compartment first-order absorption model. Age, sex, race and hepatic function were not found to be significant covariates on glasdegib PK parameters, unlike the baseline percentage of bone marrow blasts, creatinine renal clearance and use of CYP3A4 inhibitors. However, these variation factors were not considered to alter glasdegib PK in a clinically meaningful way at the recommended 100 mg daily dose.

Initial clinical trials did not measure oral bioavailability of glasdegib, thus, Shaik et al. ran an open-labeled, phase I, randomized, 2-sequence, 2-treatment, 2-period, crossover study in healthy volunteers under fasting conditions to quantify this parameter (NCT03270878, 86). Drug plasma concentrations were monitored by HPLC-MS in 12 subjects who received either 100 mg p.o. or 50 mg i.v. glasdegib. After a washout period of 6 days or more, the subjects received the treatment they did not get during the first period. The absolute oral bioavailability of glasdegib was 77.12 % and other PK parameters values were comparable to those measured in the previous phase I trials (\(T_{\text{max}} = 1.52 \text{ h}; V_d = 199.6 \text{ L}; T_{1/2} = 14.3 \text{ h}\)). The same authors also showed, through two other phase I open-label studies on healthy subjects, that neither the formulation (small- or large-particle size tablets and oral solution), nor the food intake, nor the coadministration of an acid-reducing agent (rabeprazole) had a clinically meaningful impact on oral bioavailability and pharmacokinetics of glasdegib (87, 88).

Other PK parameters of glasdegib were studied by Lam et al. in a single-dose, open-label phase I clinical trial (NCT02110342), through the administration of \(^{14}\text{C}-\text{glasdegib} (100 \text{ mg oral dose containing ~ } 3.7 \text{ kBq}) \text{ in 6 healthy volunteers (89). The mean } T_{\text{max}} \text{ in plasma was measured at } 0.75 \text{ h post-administration and the mean } T_{1/2} \text{ of total radioactivity was } 14.2 \text{ h, slightly shorter than previously stated (50). Hepatic metabolism, with particular involvement of CYP3A4, was confirmed as the main clearance pathway of glasdegib, primarily forming hydroxy, N-desmethyl and N-glucuronide primary metabolites. These components represented < } 10 \% \text{ of circulating radioactivity in plasma. Renal and faecal routes tended to contribute almost equally to glasdegib elimination (49 and 42 } \% \text{ of the administered dose, respectively).}

Effects of strong CYP3A4 inhibitors on the metabolism of glasdegib were studied in depth by Shaik et al. in a crossover protocol (NCT01749085) where healthy volunteers received a single oral administration of 200 mg glasdegib, in either a fasted or fed state, spaced by an 8-day washout. Subsequently, subjects received 400 mg ketoconazole by oral route once daily for 7 days and 200 mg glasdegib on day 4 (90). Administration of glasdegib
**Table III. Completed pharmacokinetics clinical trials involving glasdegib**

<table>
<thead>
<tr>
<th>Phase</th>
<th>Study cohort</th>
<th>Patients (n)</th>
<th>Regimen</th>
<th>Primary outcome measures</th>
<th>Study (NCT number)</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy volunteers</td>
<td>12</td>
<td>GD 100 mg oral or 50 mg IV single dose</td>
<td>AUC&lt;sub&gt;0-alt&lt;/sub&gt; (time frame: 5 days)</td>
<td>NCT03270878</td>
<td>86</td>
<td></td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>GD 100 mg single dose</td>
<td>AUC&lt;sub&gt;0-alt&lt;/sub&gt; C&lt;sub&gt;max&lt;/sub&gt;; Cumulative recovery of radioactivity in excreta; Radioactivity in blood; Urine GD PK parameters (time frame: 7 days for all parameters)</td>
<td>NCT02110342</td>
<td>89</td>
<td></td>
</tr>
<tr>
<td></td>
<td>24</td>
<td>GD 50 or 100 mg/day + rabeprazole 40 mg/day</td>
<td>AUC&lt;sub&gt;0-alt&lt;/sub&gt; C&lt;sub&gt;max&lt;/sub&gt; (time frame: 5 days for all parameters)</td>
<td>NCT03130556</td>
<td>88</td>
<td></td>
</tr>
<tr>
<td></td>
<td>14</td>
<td>GD 200 mg/day + ketoconazole 400 mg/day</td>
<td>AUC&lt;sub&gt;0-alt&lt;/sub&gt; C&lt;sub&gt;max&lt;/sub&gt; (time frame: 8 days for all parameters)</td>
<td>NCT01749085</td>
<td>90</td>
<td></td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>GD 100 mg/day + rifampicin 600 mg/day</td>
<td>AUC&lt;sub&gt;0-alt&lt;/sub&gt; C&lt;sub&gt;max&lt;/sub&gt; (time frame: 5 days)</td>
<td>NCT02430545</td>
<td>92</td>
<td></td>
</tr>
<tr>
<td></td>
<td>36</td>
<td>GD 150-300 mg single dose + moxifloxacin 400 mg or + placebo</td>
<td>Post-dose placebo corrected QTcF intervals from ECG traces following glasdegib dosing (time frame: 120 h per period)</td>
<td>NCT03162900</td>
<td>95, 96</td>
<td></td>
</tr>
<tr>
<td>Renal impairment</td>
<td>18</td>
<td>GD 100 mg single dose</td>
<td>AUC&lt;sub&gt;0-alt&lt;/sub&gt; C&lt;sub&gt;max&lt;/sub&gt; (time frame: 6 days)</td>
<td>NCT03596567</td>
<td>111</td>
<td></td>
</tr>
<tr>
<td>Hepatic impairment</td>
<td>24</td>
<td>GD 100 mg single dose</td>
<td>AUC&lt;sub&gt;0-alt&lt;/sub&gt; C&lt;sub&gt;max&lt;/sub&gt; (time frame: 6 days)</td>
<td>NCT03627754</td>
<td>110</td>
<td></td>
</tr>
</tbody>
</table>

GD – glasdegib; AUC<sub>0-alt</sub> – dose-normalized area under curve from time zero to extrapolated infinite time; AUC<sub>0-t</sub> – Area under the curve from time zero to last measured time point; C<sub>max</sub> – maximum observed plasma concentration; QTcF – Frederic's formula corrected QTc.
concomitantly with a high-fat, high-calorie meal caused a 13 % lower $AUC_{0\text{-inf}}$ and 34 % lower $C_{\text{max}}$ compared with glasdegib alone. On the contrary, administration of glasdegib in the presence of ketoconazole resulted in a 140 % higher $AUC_{0\text{-inf}}$ and 40 % higher $C_{\text{max}}$ compared with glasdegib alone. Whereas the influence of food was not considered clinically meaningful, caution should be used in the case of concomitant administration of strong CYP3A4 inhibitors with glasdegib (91).

The influence of strong CYP3A4 inducers was also explored by the same team in an open-label, fixed sequence, two-period phase I study (NCT02430545, 92). On period 1 (5 days), 12 healthy volunteers received 100 mg oral glasdegib on day 1. On period 2 (12 days), subjects were administered 600 mg oral rifampicin from day –6 to day 4 and 100 mg glasdegib on day 1 (washout was 11 days between the 2 doses of glasdegib). With rifampicin, a 29.6 % and 64.7 % reduction was observed in $AUC_{0\text{-inf}}$ and $C_{\text{max}}$ of glasdegib, respectively. Mean half-life decreased from 13.4 h to 5.1 h and apparent oral clearance increased from 12.3 to 41.4 L h$^{-1}$. Thus, the association between glasdegib and CYP3A4 inducers should be avoided. If concomitant use can’t be avoided, the dose of glasdegib can be doubled and then readjusted 7 days after the inducer is stopped (91).

A summary of clinical trials investigating the pharmacokinetics of glasdegib is provided in Table III.

Safety

The most commonly observed adverse effects of glasdegib in clinical trials were hematologic disorders (anaemia, febrile neutropenia, thrombocytopenia), nausea, decreased appetite, fatigue, muscle spasms, diarrhea and pneumonia (47, 50, 51). Most of these AEs appeared to be exposure-dependent (93). In the randomized arm of the BRIGHT AML 1003 study (26), grade 3–4 AEs occurred in 64.3 and 56.1 % of patients in the glasdegib + LDAC group and in the LDAC group, respectively. Much rarer events were also observed, such as abnormal Frederica’s QTc (in both groups), serious acute kidney injury, serious muscle spasm or elevation of liver enzymes (in combination therapy group). Grade 5 AEs were reported in 28.6 and 41.5 % of patients in these groups, respectively. AEs leading to a dose reduction or temporary treatment interruption were reported in 26.2 and 56.0 % of patients in the glasdegib + LDAC group and in 0 and 31.7 % of patients in the LDAC group. The proportions of serious AEs were relatively similar between the two treatment groups (78.6 % with combination therapy and 78 % with LDAC alone), moreover, permanent treatment discontinuation were less frequent in glasdegib + LDAC group than in LDAC group (35.7 and 46.3 %, respectively). Although glasdegib was associated with significant toxicities, most adverse events were managed with dose interruption or dose modification. In routine clinical practice, a dose modification should be considered in case of G2 muscle-related AE, haematologic toxicity, G3 nonhaematologic AEs or QT interval prolongation (91). In a brief report, Tavares et al. highlighted significant toxicities of glasdegib plus LDAC in compassionate use in 6 high-risk and heavily pretreated AML patients (94). Although this observation was made in a small number of patients, it could suggest a poorer tolerance of this treatment protocol in the salvage setting than in previously untreated patients.

Concerning the influence of glasdegib on QTc interval, Masters et al. led a phase I study (NCT03162900) on 36 healthy volunteers who received a single dose of 150 or 300 mg glasdegib, 400 mg moxifloxacin (positive control) and placebo, according to 4 different
administration sequences (95, 96). None of the subjects reached Frederica’s formula corrected QTc (QTcF) interval ≥ 480 s or an increased baseline in QTcF interval ≥ 30 ms after the administration of any treatment (mean differences in QTcF between glasdegib and placebo systematically < 20 ms). Thus, although glasdegib had an effect on cardiac repolarization, it was below the 20 ms threshold of clinical significance usually set in an oncology context (97, 98).

Based on its mechanism of action, like other HH pathway inhibitors (99, 100), glasdegib could cause foetal harm and severe birth defects when administered to pregnant women, although there are no clinical data on its impact in this patients population. Its use in women of childbearing potential should therefore be concomitant with an effective contraceptive solution, continued for at least 30 days after the last administration. In males, glasdegib may be present in semen, which can be a source of exposure for female partners with reproductive potential. Because it binds significantly to plasma proteins, the fraction of glasdegib found in milk during breastfeeding is likely to be low; however, no clinical data are available for confirmation (101). In view of the potential adverse effects in breastfed children, breastfeeding is not recommended during treatment with glasdegib and for at least one week after the last dose.

**Dosing, administration and counseling points**

Glasdegib is available under the brand-name DAURISMO as oral 25 mg or 100 mg film-coated tablets that may be taken with or without food. Only one tablet should be taken for the recommended dose of 100 mg daily in combination with LDAC (51), whereas the administration of two 25 mg tablets should be considered in case of dosage reduction based on safety and tolerability. A missed dose can be made up unless more than 10 h have passed since the scheduled administration time. Patients should be encouraged to adhere to a roughly consistent administration schedule each day.

Pharmacists are the leading healthcare professionals in counseling patients about their treatment with glasdegib as they can help prevent and guide the management of AEs associated with this therapy. Concerning the management of common non-haematologic AEs, patients should receive proper counseling on the use of supporting care medications or nonpharmacologic management strategies adapted to the SMOi therapeutic class (102–104). The early identification of non-haematologic grade 3 AEs could allow the rapid interruption of treatment until the symptoms diminish or disappear (91). A review of concomitant treatments with glasdegib could also be important to limit the risk of drug-drug interactions, especially with inducers or inhibitors of CYP3A4, QT-prolonging agents or P-glycoprotein substrates (90–92).

**Place in therapy**

Although it can occur in patients of any age, AML is mainly a disease of older adults (105). Privileged care for patients with newly diagnosed AML consist of an intensive induction chemotherapy strategy, however, a large proportion of patients is not eligible for these treatments (106). As well as AZA and decitabine, the combination of glasdegib with LDAC is now one of the therapeutic alternatives in older patients and those ineligible for IC (107), particularly because of its notable effectiveness on overall survival compared to
Table IV. Ongoing clinical trials with results pending and future clinical trials with glasdegib

<table>
<thead>
<tr>
<th>Title</th>
<th>NCT number</th>
<th>Phase</th>
<th>Estimated enrollment (n)</th>
<th>Study cohort</th>
<th>Regimen</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glasdegib (PF-04449913) with temozolomide in newly diagnosed glioblastoma</td>
<td>NCT03466450</td>
<td>1b/2</td>
<td>75</td>
<td>Glioblastoma</td>
<td>Radiotherapy (STUPP) + TMZ 75 mg/m² d₁−d₄₂ + GD 100, 150 or 200 mg/day</td>
<td>Recruiting</td>
</tr>
<tr>
<td>Glasdegib in refractory patients with sclerotic chronic graft-versus-host disease</td>
<td>NCT03415867</td>
<td>1b/2</td>
<td>21</td>
<td>Sclerodermoid chronic GVHD</td>
<td>GD 25–200 mg/day</td>
<td>Active, not recruiting</td>
</tr>
<tr>
<td>Glasdegib for chronic graft-versus-host disease</td>
<td>NCT0411497</td>
<td>1/2</td>
<td>20</td>
<td>Chronic GVHD, fasciitis</td>
<td>GD 100 mg/day</td>
<td>Recruiting</td>
</tr>
<tr>
<td>OX40, venetoclax, avelumab, glasdegib, gemtuzumab ozogamicin and azacitidine in treating patients with relapsed or refractory acute myeloid leukemia</td>
<td>NCT03390296</td>
<td>1b/2</td>
<td>138</td>
<td>Recurrent AML</td>
<td>Arm A: anti-OX40 antibody PF-04518600 IV d₁, d₁₄&lt;br&gt;Arm B: AZA IV d₁−d₇ + GO IV d₈ + venetoclax PO d₁−d₂₈&lt;br&gt;Arm C: AZA IV d₁−d₇ + GO IV d₈ + avelumab IV d₁−d₁₄&lt;br&gt;Arm D: AZA IV d₁−d₇ + venetoclax PO d₁−d₂₈ + avelumab IV d₁−d₁₄&lt;br&gt;Arm E: AZA IV d₁−d₇ + avelumab IV d₁−d₁₄ + anti-OX40 antibody PF-04518600 IV d₈, d₁₄&lt;br&gt;Arm F: GO IV d₁, d₄, d₇ + GD PO d₁−d₂₈</td>
<td>Recruiting</td>
</tr>
<tr>
<td>A study of PF-04449913 in Japanese patients with select hematologic malignancies</td>
<td>NCT02038777</td>
<td>1</td>
<td>48</td>
<td>AML, MDS</td>
<td>Cohort 1: GD 25 or 50 or 100 mg/day&lt;br&gt;Cohort 2: GD + LDAC 20 mg, 2/d, d₁−d₁₀&lt;br&gt;Cohort 3: GD + AraC 100 mg/m² d₁−d₇ + DNR 60 mg/m² d₁−d₇, then GD + AraC 1 g/m² d₉, d₅&lt;br&gt;Cohort 4: GD + AZA 75 mg/m² d₁−d₇&lt;br&gt;Cohort 5: GD alone for one patient rolled-over from another trial&lt;br&gt;Cohort 6: GD + LDAC 20 mg, 2/d, d₁−d₁₀ (expansion cohort)</td>
<td>Active, not recruiting</td>
</tr>
</tbody>
</table>
A combination study of PF-04449913 (glasdegib) and azacitidine in untreated MDS, AML and CMML patients (BRIGHT 1012)

<table>
<thead>
<tr>
<th>Study ID</th>
<th>Phase</th>
<th>Sites</th>
<th>AML/MDS/CMML</th>
<th>Description</th>
<th>Status</th>
</tr>
</thead>
</table>
| NCT02367456 | 2     | 170   | AML/MDS/CMML | Arm A (MDS): GD 100 mg/day + AZA 75 mg/m² d₁−d₇  
Arm B (AML): GD 100 mg/day + AZA 75 mg/m² d₁−d₇ | Active, not recruiting |

GLAD-AML - Glasdegib (PF-04449913) with two standard decitabine regimens for older patients with poor-risk acute myeloid leukemia

<table>
<thead>
<tr>
<th>Study ID</th>
<th>Phase</th>
<th>Sites</th>
<th>AML</th>
<th>Description</th>
<th>Status</th>
</tr>
</thead>
</table>
| NCT04051996 | 2     | 46    | AML | Arm A: GD 100 mg/day + DAC 20 mg/m² IV, 5 days  
Arm B: GD 100 mg/day + DAC 20 mg/m² IV, 10 days | Active, not recruiting |

CPX-351 and glasdegib for newly diagnosed acute myelogenous leukemia with MDS related changes or therapy-related acute myeloid leukemia

<table>
<thead>
<tr>
<th>Study ID</th>
<th>Phase</th>
<th>Sites</th>
<th>AML</th>
<th>Description</th>
<th>Status</th>
</tr>
</thead>
</table>
| NCT04231851 | 2     | 30    | AML | Induction: CPX-351 44 mg/m²; 100 mg/m² IV d₁, d₅  
Consolidation: CPX-351 29 mg/m²; 65 mg/m² IV d₅, d₉ + GD 100 mg d₁−d₉ | Recruiting              |

Gemtuzumab ozogamicin in induction and glasdegib in postremission therapy in patients with AML (acute myeloid leukemia)

<table>
<thead>
<tr>
<th>Study ID</th>
<th>Phase</th>
<th>Sites</th>
<th>AML</th>
<th>Description</th>
<th>Status</th>
</tr>
</thead>
</table>
| NCT04093505 | 3     | 252   | AML | Regimen 1: GO 3 mg/m² d₁, d₄, d₇  
+ GD 100 mg or placebo d₁−d₇  
Regimen 2: GO 3 mg/m² d₁  
+ GD 100 mg or placebo, d₁−d₇ | Not yet recruiting |

Gemtuzumab chemotherapy MRD levels; glasdegib post-transplant, adult untreated, de novo, fav-interm risk AML

<table>
<thead>
<tr>
<th>Study ID</th>
<th>Phase</th>
<th>Sites</th>
<th>AML</th>
<th>Description</th>
<th>Status</th>
</tr>
</thead>
</table>
| NCT04168502 | 3     | 414   | AML | Induction: GO 3 mg/m² d₁, d₄, d₇  
+ AraC 200 mg/m² d₁−d₇  
Consolidation: GO 3 mg/m² d₁  
+ AraC 500 mg/m², 2/d, d₁−d₇  
+ GD 100 mg/day or clinical observation only | Not yet recruiting |

A study evaluating intensive chemotherapy with or without glasdegib or azacitidine with or without glasdegib in patients with previously untreated acute myeloid leukemia (BRIGHT AML1019)

<table>
<thead>
<tr>
<th>Study ID</th>
<th>Phase</th>
<th>Sites</th>
<th>AML</th>
<th>Description</th>
<th>Status</th>
</tr>
</thead>
</table>
| NCT03416179 | 3     | 720   | AML | - Intensive study: Placebo or GD 100 mg/day  
+ ‘7+3’ AraC 100 mg/m² IV + DNR 60 mg/m² d₁−d₇  
- Non-intensive study: Placebo or GD 100 mg/day  
+ AZA 75 mg/m², SC or IV, d₁−d₇ | Active, not recruiting |

LDAC alone (26, 73). In recent years, FDA also approved several new targeted therapies such as gemtuzumab ozogamicin, venetoclax, ivosidenib or midostaurin to treat patients with newly diagnosed AML (108). In this very shifting landscape, the selection of patients best suited for these treatments is an essential questioning. Cortes et al. published expert recommendations suggesting that glasdegib in combination with LDAC could effectively be considered for patients aged ≥ 75, with poorer risk profiles and prognostic scores, ineligible for IC, with secondary AML or who received prior HMA for MDS (109). Patients with hepatic or renal impairment (110, 111) and severe cardiac disease could also benefit from this combination therapy. Despite a monthly list price of 16,925 USD for glasdegib, the budget impact of including glasdegib plus LDAC as first-line treatment from a US health plan perspective was estimated to be low for the US payers, as the eligible patient population size remains small (112).

CONCLUSIONS

Glasdegib is a recent targeted anticancer agent for the management of AML, particularly in elderly patients not eligible for IC. In combination with LDAC, the use of glasdegib almost doubled the median overall survival compared to LDAC alone in phase II clinical trials that led to the FDA approval of glasdegib (113). Definitive results of the BRIGHT AML 1019 phase III clinical trial, when available, will provide new information on the risk/benefit profile of glasdegib and on its place in the AML therapeutic strategy in combination with cytotoxic agents such as cytarabine plus daunorubicin (which remain the reference IC regimen for AML patients). Its oral administration route as well as its manageable safety profile could allow better medication adherence and quality of life, especially if a therapeutic education of patients on common AEs is set up. Going forward, several clinical trials involving glasdegib are currently underway (Table IV), investigating its use as monotherapy or in combination with other anticancer agents in both haematological (NCT04231851, NCT04168502, NCT04051996 (114), NCT04655391, NCT04093505, NCT03390296) and solid cancers (NCT03466450).

Acknowledgements. – The authors thank Dr. Emmanuel Deshayes from the Montpellier Cancer Institute for critical comments on this manuscript.

REFERENCES

1. C. Nüsslein-Volhard and E. Wieschaus, Mutations affecting segment number and polarity in Droso-
sophila, Nature 287 (1980) 795–801; https://doi.org/10.1038/287795a0
2. R. Machold, S. Hayashi, M. Rutlin, M. D. Muzumdar, S. Nery, J. G. Corbin, A. Gritli-Linde, T. Del-
lovade, J. A. Porter, L. L. Rubin, H. Dudek, A. P. McMahon and G. Fishell, Sonic hedgehog is re-
https://doi.org/10.1016/s0896-6273(03)00561-0
3. C. Torroja, N. Gorfinkiel and I. Guerrero, Mechanisms of Hedgehog gradient formation and in-
2472; https://doi.org/10.1101/gad.1693608


65. H. Döhner, M. Lübbert, W. Fiedler, L. Fouillard, A. Haaland, J. M. Brandwein, S. Lepretre, O. Re- 
F. Voss, T. Taube, H. Fritsch and J. Maertens, Randomized, phase 2 trial of low-dose cytarabine 
with or without volasertib in AML patients not suitable for induction therapy, Blood 124 (2014) 
1426–1433.; https://doi.org/10.1182/blood-2014-03-560557

Clark and D. Milligan, A randomised comparison of the novel nucleoside analogue sapacitabine 
with low-dose cytarabine in older patients with acute myeloid leukaemia, Leukemia 29 (2015) 
1312–1319; https://doi.org/10.1038/leu.2015.38

67. M. Heiblig, M. Elhamri, I. Tigaud, A. Plesa, F. Barraco, H. Labussière, S. Ducastelle, M. Michallet, 
F. Nicolini, C. Plesa, E. Wattel, G. Salles and X. Thomas, Treatment with low-dose cytarabine in 
elderly patients (age 70 years or older) with acute myeloid leukaemia: a single institution experi-

68. A. T. Fathi, Glasdegib with low-dose cytarabine: a new upfront option for the vulnerable AML 

69. C. Papayannidis, B. D. Smith, M. Heuser, P. Montesinos, M. A. Sekeres, A. Oriol, G. Schiller, A. 
Candoni, C. Jamieson, C. J. Hoang, W. W. Ma, M. Zeremski, A. O’Connell, G. Chan and J. E. Cortes, 
Low-dose cytarabine with or without glasdegib in newly diagnosed patients with acute myeloid 
leukemia: long-term analysis of a phase 2 randomized trial, Clin. Lymphoma Myeloma Leuk. 19 

Pérez-Simón, C. J. Hoang, W. Wendy Ma, M. Zeremski, A. O’Connell, G. Chan and J. E. Cortes, 
Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary 
acute myeloid leukemias: long-term analysis of a phase 2 randomized trial, Clin. Lymphoma Myeloma Leuk. 19 

71. C. D. DiNardo, K. W. Pratz, A. Letai, B. A. Jonas, A. H. Wei, M. Thirman, M. Arellano, M. G. Frat-
tini, H. Kantarjian, R. Popovic, B. Chyla, T. Xu, M. Dunbar, S. K. Agarwal, R. Humerrickhouse, M. 
Mabry, J. Potluri, M. Konopleva and D. A. Pollyea, Safety and preliminary efficacy of venetoclax 
with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leu-
org/10.1016/S1470-2045(18)30010-X

72. A. Wolska-Washer and T. Robak, Glasdegib in the treatment of acute myeloid leukaemia, Future 

73. M. Heuser, T. Robak, P. Montesinos, B. Leber, W. M. Fiedler, D. A. Pollyea, A. Brown, A. O’Connell, 
W. Ma, G. Chan and J. E. Cortes, Glasdegib (GLAS) plus low-dose cytarabine (LDAC) in AML or 
MDS: BRIGHT AML 1003 final report and four-year overall survival (OS) follow-up, J. Clin. Oncol. 

A. Sekeres, D. A. Pollyea, R. Ferdinand, W. W. Ma, T. O’Brien, A. O’Connell, G. Chan and M. Heuser, 
Survival outcomes and clinical benefit in patients with acute myeloid leukaemia treated with 
glasdegib and low-dose cytarabine according to response to therapy, J. Hematol. Oncol. 13 (2020) 
92; https://doi.org/10.1186/s13045-020-00929-8

75. E. S. Wang, M. Heuser, M. A. Sekeres, C. Papayannidis, A. Candoni, A. Merchant, A. Brown, A. 
O’Connell, W. Ma, G. Chan and J. E. Cortes, Effect of early blood counts on overall survival (OS) 
following glasdegib + LDAC in newly diagnosed AML: BRIGHT AML 1003 post hoc analysis, J. 

76. G. Tremblay, T. Westley, J. C. Cappelleri, B. Arondekar, G. Chan, T. J. Bell and A. Briggs, Overall 
Survival of glasdegib in combination with low-dose cytarabine, azacitidine, and decitabine 
among adult patients with previously untreated AML: comparative effectiveness using simulated 

31


97. N. Sarapa and M. R. Britto, Challenges of characterizing proarrhythmic risk due to QTc prolongation induced by nonadjuvant anticancer agents, Expert Opin. Drug Saf. 7 (2008) 305–318; https://doi.org/10.1517/14740338.7.3.305


